![](https://medcitynews.com/wp-content/uploads/sites/7/2021/08/its-a-heart.jpg)
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots
Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer advantages over anticoagulants currently sold by some of its …